Biomerica, Inc. (NASDAQ:BMRA) Short Interest Update

Biomerica, Inc. (NASDAQ:BMRA) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 61,056 shares, a decline of 17.0% from the March 31st total of 73,534 shares. Based on an average trading volume of 29,780 shares, the short-interest ratio is currently 2.1 days. Approximately 2.4% of the company’s stock are sold short.

Biomerica Price Performance

Shares of BMRA traded up $0.01 during midday trading on Friday, reaching $2.19. The stock had a trading volume of 5,507 shares, compared to its average volume of 15,645. The company has a market cap of $6.77 million, a price-to-earnings ratio of -2.46 and a beta of 0.20. The company’s fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $2.38. Biomerica has a 1-year low of $1.87 and a 1-year high of $4.60.

Biomerica (NASDAQ:BMRA) last issued its earnings results on Monday, April 13th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.76. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $3.63 million. Biomerica had a negative net margin of 96.49% and a negative return on equity of 98.14%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC lifted its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the period. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 at the end of the most recent reporting period. 22.28% of the stock is currently owned by institutional investors and hedge funds.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.